Skip to Main Content

Editor’s note: A recording of the conversation is embedded below. 

Each week, STAT+ subscribers get exclusive access to live discussions with STAT reporters and leaders in health and medicine.


This week, Adam Feuerstein and Damian Garde from STAT’s national biotech team will be discussing the FDA review of Biogen’s Alzheimer’s treatment, aducanumab, and taking your questions live.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!